Preoperative Ketamine and Perioperative Depression

• ClinicalTrials.gov Identifier: NCT04220125
• Recruitment Status: Withdrawn
• First Posted: January 7, 2020
• Last Update Posted: February 6, 2023
• Sponsor: Northwestern University
• Information provided by (Responsible Party): Charles W Hogue, Northwestern University

Study Description

Brief Summary:

Depressive symptoms, in patients with a life history of major depressive disorder (MDD), are very common in the general population, and are especially so in elderly adults undergoing surgery.Symptoms of depression at the time of surgery is associated with risk for postoperative complications.Attenuating depressive symptoms in patients undergoing surgery is thus a plausible but not adequately tested strategy for improving patient postoperative outcomes. Conventional treatment of depression takes weeks and, therefore, is not always a realistic option, particularly when surgery is urgent. Importantly, there are currently no guidelines for diagnosing and managing MDD in surgical patients. Given its association with complications including perioperative cognitive disorders such as delirium, and over longer periods of time with dementing disorders, the feasibility and efficacy of quick-acting treatments for depressive symptoms in surgical patients are direly needed. This need is particularly acute given the rising number of elderly patients undergoing surgery who are prone to depression and surgical complications.

Aim 1: To assess the feasibility of enrolling patients in a clinical trial where a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) or midazolam (0.045 mg/kg) is given 1 to 3 days before surgery in the preoperative clinic as a strategy to improve depressive symptoms during the perioperative period.

Aim 2: To obtain estimates of the variability in improvements of depressive symptoms (increase from baseline in MADRS score ≥ 2)1 day after surgery for patients given a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) 1 to 3 days before surgery compared with midazolam 0.045 mg/kg.

Aim 3: To assess for the safety and tolerability of administration of a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) given 1 to 3 days before surgery in the preoperative clinic (as an outpatient) by assessment of dysphoric symptoms or other complications including the need for hospitalization.

Hypothesis:

Aim 1: Hypothesis: Patients with preoperative depressive symptoms can be identified before surgery and successfully enrolled in a clinical trial comparing a sub-anesthetic dose of ketamine versus midazolam for improving perioperative depressive symptoms.

Aim 2: Hypothesis: Compared with midazolam, a sub-anesthetic dose of ketamine given preoperatively leads to an improvement in MADRS score ≥ 2 on day 1 after surgery.

Aim 3: Hypothesis: Compared with midazolam, a sub-anesthetic dose of ketamine is not associated with dysphoria or other complications.

Condition or disease	Intervention/treatment	Phase
Depressive Disorder	Drug: Ketamine Group; Drug: Midazolam injection	Phase 4

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Care Provider)
• Primary Purpose: Treatment
• Official Title: Preoperative Ketamine as a Strategy to Decrease Perioperative Depression During the Perioperative Period: a Randomized Active Controlled Pilot Study
• Actual Study Start Date: September 1, 2022
• Actual Primary Completion Date: February 2, 2023
• Actual Study Completion Date: February 2, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Ketamine Group; Ketamine 0.5 mg/kg over 40 min via intravenous catheter.	Drug: Ketamine Group; Ketamine intravenous administration 0.5 mg/kg over 40 minutes.; Other Name: Ketamine
Active Comparator: MIdazolam Group; Midazolam 0.045 mg/kg administered via intravenous catheter.	Drug: Midazolam injection; Midazolam intravenous administration 0.045 mg/kg IV over 40 minutes.; Other Name: Midazolam

Outcome Measures

Primary Outcome Measures :

1. Change in depressive symptoms in the perioperative period. [ Time Frame: 3 Days before surgery to 30 days after the surgical procedure ]
   Ketamine administration changes depressive symptoms perioperatively. Measured using Depression will be measured with the Montgomery-Asberg Depression Scale (MADRS) scale. Scale ranges from 0 no depresson- 60 severe depression.

Secondary Outcome Measures :

1. Change in depressive symptoms 1 day after surgery [ Time Frame: 24 hours after surgical procedure ]
   Change in depressive symptoms using MADRS questionnaire measured with the Montgomery-Asberg Depression Scale scale. Scale ranges from 0 no depresson- 60 severe depression.
2. Safety analsysis of administration of a sub-anesthetic dose of ketamine: CADSS [ Time Frame: 65 minutes after study drug has been infused. ]
   To assess for the safety of administration of a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) given 1 to 3 days before surgery in the preoperative clinic (as an outpatient) by assessment of dysphoric symptoms or other complications including the need for hospitalization. The Clinician-Administered Dissociative States Scale CADSS is a 27 question survey ,19 which are completed by the subject on a scale of 0 -4 likert scale for a possible score 0- good 76 poor and 9 questions completed by the assessor (scored yes or no).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female patients age ≥ 65 years
• Planned lumbar surgery for degenerative disc disease or spinal stenosis involving 2 or more levels
• A life history of MDD (DSM-5 criteria) and a MADRS score ≥20
• Mini-Mental State Examination (MMSE) score ≥ 15
• MMSE is between15-26
• Ability to understand English.

Exclusion Criteria:

• MMSE < 15
• History of psychosis
• Poorly controlled hypertension
• Pre-existing aneurysmal vascular disorders
• Cocaine or other illicit drug use.

Contacts and Locations

Sponsors and Collaborators

Northwestern University

Investigators

• Principal Investigator: Charles Hogue, MD; Northwestern University

More Information

• Responsible Party: Charles W Hogue, Chair, Department of Anesthesiology, Northwestern University
• ClinicalTrials.gov Identifier: NCT04220125
• Other Study ID Numbers: STU00211219
• First Posted: January 7, 2020
• Last Update Posted: February 6, 2023
• Last Verified: February 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Depressive Disorder; Mood Disorders; Mental Disorders; Midazolam; Ketamine; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anesthetics, Dissociative; Anesthetics, Intravenous; Anesthetics, General; Anesthetics; Central Nervous System Depressants; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Adjuvants, Anesthesia; Hypnotics and Sedatives; Anti-Anxiety Agents; Tranquilizing Agents; Psychotropic Drugs; GABA Modulators; GABA Agents